Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established. Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed. METHODS: In this international, double-blind trial, we randomly assigned patients with heart failure and a left ventricular ejection fraction of 40% or greater, in a 1:1 ratio, to receive finerenone (at a maximum dose of 20 mg or 40 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of total worsening heart failure events (with an event defined as a first or recurrent unplanned hospitalization or urgent visit for heart failure) and death from cardiovascular causes. The components of the primary outcome and safety were also assessed. RESULTS: Over a median follow-up of 32 months, 1083 primary-outcome events occurred in 624 of 3003 patients in the finerenone group, and 1283 primary-outcome events occurred in 719 of 2998 patients in the placebo group (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P = 0.007). The total number of worsening heart failure events was 842 in the finerenone group and 1024 in the placebo group (rate ratio, 0.82; 95% CI, 0.71 to 0.94; P = 0.006). The percentage of patients who died from cardiovascular causes was 8.1% and 8.7%, respectively (hazard ratio, 0.93; 95% CI, 0.78 to 1.11). Finerenone was associated with an increased risk of hyperkalemia and a reduced risk of hypokalemia. CONCLUSIONS: In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo. (Funded by Bayer; FINEARTS-HF ClinicalTrials.gov number, NCT04435626.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Of the enrolled participants, 41% had type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
The cited source says what the claim attributes to it.
In the citing paper
“The selective nonsteroidal MRA finerenone was examined in the Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF) trial of people with symptomatic HFpEF (ejection fraction ≥40%) and was found to reduce the risk of”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationPitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationEplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citationCardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 601–700 of 892
Incretin-Based Therapies and Heart Failure Outcomes
Savarese, G., & Butler, J. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.022
Die ESC-Leitlinien zur Herzinsuffizienz im Spiegel aktueller Evidenz
Ghorani, H. A., Böhm, M., & Abdin, A. (2025) · Kardiologie up2date · doi:10.1055/a-2461-7287
Khan, R., Pachchipulusu, V., Narayanan, D. H., Rahul, C., tejaswini, H. K., Patel, P., Vanguru, R. V., Kalpeshbhai, P. Y., Lakshmi, S., Nandakishor, N., et al. (2025) · medRxiv · doi:10.1101/2025.09.13.25335677
Raby, J., Aggour, H., George, M., Glatzel, H., Fidock, B., Winter, M., Quek, K., Federman, S., Chaplin, J., Kononen, M., et al. (2025) · Open Heart · doi:10.1136/openhrt-2025-003432 · Cited by 2
“However, as we found that all LVEF groups benefited from postdischarge HF specialist care, this uncertainty should not detract from the key messages of our study.”
What's New in Heart Failure? August 2025
Aimo, A., Codina, P., Lee, M. M. Y., Tomasoni, D., & Böhm, M. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70020
Jelwan, Y. A., Cao, T., Yao, Z., Burka, S., Erharbor, J., Berning, P., Dzaye, O. D. A., & Blaha, M. J. (2025) · medRxiv · doi:10.1101/2025.10.02.25337213
Riccardi, M., Pabón, M. A., Vardeny, O., Vaduganathan, M., Solomon, S. D., & Inciardi, R. M. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.033
Self-citationMedical Therapy Following Transcatheter Edge-to-Edge Repair for Functional Mitral Regurgitation
Zhu, Q., & Liu, X. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.06.005
Liu, X., Wang, Z., Hua, C., Wu, Y., Tang, Y., Xiong, Y., Liu, J., Zhang, J., Lv, Q., Jiang, C., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15435
“13 These improvements were achieved through mechanisms independent of blood pressure lowering.”
Wirkt die moderne pharmakologische Herzinsuffizienztherapie antiarrhythmisch?
Boehmer, A. A., Rothe, M., & Ehrlich, J. R. (2025) · Aktuelle Kardiologie · doi:10.1055/a-2666-3061
Was ist gesichert in der medikamentösen Therapie der Herzinsuffizienz?
Soltani, S., & Bauersachs, J. K. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01998-y
Self-citationYang, M., Chimura, M., Lam, C. S. P., Senni, M., Voors, A. A., Zannad, F. M., Vaduganathan, M., Jhund, P. S., Solomon, S. D., & McMurray, J. J. V. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102705 · Cited by 1
Self-citationHulot, J. (2025) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2025.10.001
Kittleson, M. M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102760
Improving the Analysis of KCCQ Endpoints in Heart Failure Clinical Trials
Myte, R., Eriksson, J., Rensfeldt, M., Jiang, Y., Al‐Shurbaji, A., & Nyström, P. O. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00888-7
“Typically, change from baseline in KCCQ scores is analyzed using linear models such as ANCOVA or Mixed Mod - els for Repeated Measures (MMRM) assuming normally distributed data [ 8 –12].”
Aldosterone blockade after myocardial infarction: Preventing or treating heart failure?
Beygui, F. (2025) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2025.10.327
George, V., Pillai, M. H., Jacob, V., Revanth, M. P., Vasant, A., & Adnan, H. (2025) · Cureus · doi:10.7759/cureus.96616
“The RCTs that were deemed relevant to the review were DELIVER [15], PRESERVED-HF [16], EMPULSE [17], and SOLOIST-WHF [18] for SGLT2 inhibitors and FINEARTS-HF [19] for MRAs.”
Chatur, S., & Ezekowitz, J. A. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102719
Exercise Rehabilitation for Heart Failure and Associated Cardiomyopathies
Stahl, M. E., Weeldreyer, N. R., MacNamara, J. P., Lozano, P. F. R., & Allen, J. D. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02313-9 · Cited by 2
Overcoming Renalism: A Roadmap Towards Equitable Kidney Care
Divyaveer, S. S., Anandh, U., Vijayakumar, N. A., Venkatasubramanian, V., & Hiremath, S. S. (2025) · Indian Journal of Nephrology · doi:10.25259/ijn_119_2025
Die Diagnostik und Therapie der akuten Herzinsuffizienz: Schritt für Schritt
Wagner, J., Franz, M., & WAGNER, E. (2025) · Kardiologie up2date · doi:10.1055/a-0882-4075
Tinti, M. D., Gennaro, L. D., Limonta, R., Maria, R. D., Carigi, S., Bianco, M., Nora, C. D., Manca, P., Matassini, M. V., Rizzello, V., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248730
Perspectives on Registry-Based Research in Heart Failure: Current Status and Future Directions
Basile, C., Lindberg, F., & Savarese, G. (2025) · Korean Circulation Journal · doi:10.4070/kcj.2025.0453
“5)6) However, the benefits of these treatments in clinical practice depend largely on their effective implementation, which can be hindered by factors such as clinical inertia, limited patient adherence, and high medication costs.”
Albuminuria in Heart Failure: From Marker to Modifiable Target
Arun, A. J., Kaneki, S., Baig, M., & Frishman, W. H. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001155
Marx-Schütt, K., Forst, T. M., Birkenfeld, A. L., Zirlik, A., Müller‐Wieland, D., & Marx, N. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8456
Yaku, H. (2025) · Kosin Medical Journal · doi:10.7180/kmj.25.134
de la Puente, J. B. (2025) · Diabetes práctica · doi:10.52102/diabet/manejo.erc.art2
Carretero-Anibarro, E. (2025) · Diabetes práctica · doi:10.52102/diabet/manejo.erc.art3
Anagnostopoulou, V., Sharma, A., & Pellicori, P. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102842
Finerenone across the HFpEF and HFmrEF spectrum: a step towards multi-pillar care?
Merlo, M., Soranzo, E., & Sinagra, G. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuaf021
Practical Prescribing: Potassium sparing diuretics
Anisman, S. D., Erickson, S. B., & Luneau, A. K. (2026) · BMJ · doi:10.1136/bmj-2025-085905
“20 This benefit is seen early in treatment, 21 particularly in patients with worsening disease, 22 without adversely affecting long term renal function, 23 and irrespective of age.”
Ipek, R., Gastl, M., & Kelm, M. (2026) · Springer eBooks · doi:10.1007/978-3-031-96019-2_30
Bianco, M., Carigi, S., Maria, R. D., Brookles, C. G., Kamgaing, W. J. M., Gennaro, L. D., Nora, C. D., Manca, P., Matassini, M. V., Rizzello, V., et al. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106728
Navigating the Intersection of HFmrEF/HFpEF and CKD
McCallum, W. I. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.102941
Segev, A., Wright, S. P., & Hawkins, N. M. (2026) · Current Heart Failure Reports · doi:10.1007/s11897-025-00723-y · Cited by 3
Evaluation and Management of Primary Aldosteronism
Salle, S. P., & Vaidya, A. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2025.12.002 · Cited by 1
Kanki, M., Vivekanantham, E., Tesch, G. H., Parslow, A. C., Cole, T. J., Fuller, P. J., Donner, D. G., Kiriazis, H., de Haan, J. B., Sun, J. M., et al. (2026) · Endocrinology · doi:10.1210/endocr/bqaf178 · Cited by 2
Marx-Schütt, K., Forst, T. M., Birkenfeld, A. L., Zirlik, A., Müller‐Wieland, D., & Marx, N. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01426-1
Revascularization of atherosclerotic renal artery stenosis in patients with heart failure
Green, D., Cleland, J. G. F., Pellicori, P., O’Keeffe, H., Lake, E., Chrysochou, C., Mello, H. M. L. E., & Kalra, P. A. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag042
Mineralocorticoid receptor antagonists
Mallart-Riancho, J., Pariente, B., Azizi, M., & Amar, L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00385-x
Tanaka, H. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134245
Lerchner, T., Roß, S., Buehning, F., Vogel, J. K., Rassaf, T., & Michel, L. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05029-x
“HF is ubiquitous distributed between males and females, as shown by landmark studies (Solomon et al. 2024; Anker et al. 2021).”
Do we need exercise echocardiography to diagnose HFpEF? Not at all
Brennan, A. C., Campbell, R., Docherty, K. F., Lee, M. M. Y., McMurray, J. J. V., Cleland, J. G. F., Petrie, M. C., & Pellicori, P. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag044
Self-citationRodríguez, J. M. F., Ortiz, M. B. A., Casado, J., Chivite, D., Romano, P. C., Alonso, R. G., Almorós, A. L., Miramontes‐González, J. P., Rangel, L. S., & Pérez-Silvestre, J. (2026) · Revista Clínica Española · doi:10.1016/j.rce.2026.502471
Early Initiation and Dose Optimization of Mineralocorticoid Receptor Antagonists in Heart Failure
Banerjee, S., Rajput, R., Shah, C. P., Raghunandan, B. K., Gupta, A., Chatterjee, S., Anne, K. P., Veer, A., Joshi, A., Raghuvanshi, A., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1299
Oßwald, H., & Mühlbauer, B. (2026) · Springer eBooks · doi:10.1007/978-3-662-72738-6_33
Zhou, H., Li, X., Zheng, Z., Tang, W., Wu, X., & Fan, C. (2026) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/14703203261427139
Beavers, C. J., & Greene, S. J. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10597-4
McGuigan, A. (2026) · Drugs & Therapy Perspectives · doi:10.1007/s40267-026-01226-z
Gallo, G., & Volpe, M. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag135
Taebi, M., Fallahtafti, P., Kakavand, N., Nematollahi, S., Daryabari, Y., Biering‐Sørensen, T., & Hosseini, K. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10594-7
Marx-Schütt, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00016-1
Ferreira, V. M. (2026) · Cureus · doi:10.7759/cureus.104817
“Beyond SGLT2i, the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) trial demonstrated that finerenone reduces cardiovascular death and HF events in patients with LVEF >40% [8].”
InfluentialVijayasimha, M., Srikanth, M., & Singh, G. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07856-9
“At the Randomised trials in HF with mildly reduced or preserved ejection fraction support the clinical benefit of finerenone [2], and post hoc analyses demonstrate clinically relevant interactions between finerenone, concomitant SGLT2 inhib - itor use, and potassium dynamics [3].”
progress, pitfalls, and perspectives
Fonseca, C., Rui, B., Fátima, F., Brenda, M., Pimenta, J., Sarmento, P., Silva‐Cardoso, J., & Brito, D. A. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Self-citationDiagnostik und Therapieansätze der Herzinsuffizienz mit erhaltener systolischer Funktion
Beyer, M., Mügge, A., Akın, İ., van Heerebeek, L., El‐Battrawy, I., & Hamdani, N. (2026) · Die Kardiologie · doi:10.1007/s12181-026-00807-6
Lemański, T., Folkerts, K., McEwan, P. C., Mernagh, P., Zemojdzin, M., & Pochopień, M. (2026) · Journal of Market Access & Health Policy · doi:10.3390/jmahp14010016
“…previous models in HF, which have used both NYHA class [26,29] and KCCQ [18–21, 25, 27, 30, 31] The model was largely informed by FINEARTS-HF, a recent, pivotal, international phase 3 trial providing evidence on the safety and efficacy of finerenone added to usual SoC therapy vs. SoC alone [13].”
InfluentialFinerenone in HFmrEF and HFpEF: modest gains in patient quality of life
Park, J. J., & Störk, S. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag084
Dhruva, Y. V., Ponnada, R. B., Pujari, B., Gupta, R., Lu, C.-H., Peddada, V. P., & Lin, C.-J. (2026) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000002072
Insuffisance cardiaque : prise en charge périopératoire
Jendoubi, A., Damy, T., & Mongardon, N. (2026) · EMC-Anesthésie réanimation/Encyclopédie médico-chirurgicale. Anesthésie, réanimation · doi:10.1016/s0246-0289(25)45652-7
Establishing four pillar treatment of chronic heart failure
Roskvist, R. P., Johnston, R., Eggleton, K. S., & Arroll, B. (2026) · BMJ · doi:10.1136/bmj.s450
“17 18 Notably, this benefit was most pronounced in participants who initiated finerenone within seven days of a worsening heart failure event(riskratio0.”
Corica, B., Battigaglia, E., Romiti, G. F., Imberti, J. F., Mei, D. A., Bonini, N., Vitolo, M., & Boriani, G. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2650525
“Compared to this previous work, our estimates included the results of the large FINEARTS-HF Trial, a recent RCT on finerenone [46] (specifically the pre-specified analysis on AF) [20], which led to almost doubling the total HF population included.”
Li, C., Kan, M., & Chen, H. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-113093
“16 However, the overall strength of evidence remains limited, and the comprehensive therapeutic outcomes and long-term efficacy of pharmacological interventions continue to be inadequate.”
Henderson, A. D., Soltani, S., Bauersachs, J. K., & Jhund, P. S. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag095
Self-citationRethinking Sudden Death in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Fonarow, G. C. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.0692
Chimura, M., McDowell, K., Jhund, P. S., Henderson, A. D., Claggett, B. L., Desai, A. S., BRINKER, M. D., Lay‐Flurrie, J., Glasauer, A., Goea, L., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.1049
Self-citationFinerenone in heart failure with ejection fraction ≥40%: state of the art and future perspectives
Llàcer, P., Marcos, M. C., Núñez, J. E., Perez-Belmonte, L. M., Pérez-Silvestre, J., Martéles, M. S., & Colet, J. C. (2026) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2026.502520
Cardiogenic Shock: Clinical Management, Outcomes and Future Directions
Aubdool, A. A., Sullivan, A. J., Jones, D. A., Mathur, A., Proudfoot, A. G., & Rathod, K. S. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13040156
“Adherence to guideline-directed medical therapy (GDMT) using ACE inhibitors, beta-blockers, SGLT2 inhibitors, and mineralocorticoid receptor antagonists (MRAs) has demonstrated significant reductions in mortality and rehospitalisations in landmark trials [107–111].”
Nonsteroidal mineralocorticoid receptor antagonists: prospects in heart failure
Ageev, F. T., Ovchinnikov, A. G., & Ageeva, S. F. (2026) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin20262101113
Economic burden associated with systemic inflammation in patients with HFmrEF/HFpEF
Adesoba, T. P., Skaar, J. R., Goss, A., Han, Y., Zhao, X., Ding, Y., Zhou, Y., & Harrington, J. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107439
Cardiovascular pharmacotherapy in 2025
Tamargo, J. L., Agewall, S., Ambrosio, G., Borghi, C., Cerbai, E., Dan, G., Drexel, H., Ferdinandy, P., Grove, E. L., Klingenberg, R., et al. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag016 · Cited by 2
Management Strategies for Congestive Heart Failure in Chronic Kidney Disease: Narrative Review
Soto-Santillán, P., Jacobo-Ruvalcaba, A., de Lay, M. W., & Orihuela-Rodríguez, Ó. (2026) · Biomedicines · doi:10.3390/biomedicines14040841
Kardiovaskuläre Pharmakotherapie im Zeitalter RNA-basierter Präzisionsmedizin
Derda, A. A., & Hohneck, A. L. (2026) · Herz · doi:10.1007/s00059-026-05375-9
Heart Failure With Preserved Ejection Fraction
Weigel, F., & Miller, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00188-6
Zhao, C., Sun, B., Xu, H., Yao, Y., Huang, F., & Liu, X. (2026) · Frontiers in Cardiovascular Medicine · doi:10.21203/rs.3.rs-9027680/v1
Managing patients with heart failure: A contemporary practice tool for pharmacists
Barry, A. R., & Koshman, S. L. (2026) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.3138/cpj-25-0119
Hage, C., Andersson, T., Christersson, C., Linde, C. M., Lund, L. H., Karlström, P., Chatziapostolou, D., Dagner, V., Granström, F., Gylling, A., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag092
“Presently GDMT is limited to SGLT2/1 inhibitors, 11 even if novel MRAs 12 and glucagon-like peptide-1 agonists 13 may be options in the future.”
Gallo, G., & Volpe, M. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag278
Llàcer, P., Marcos, M. C., Nuñez, J., Perez-Belmonte, L. M., Pérez-Silvestre, J., Marteles, M. S., & Colet, J. C. (2026) · Revista Clínica Española · doi:10.1016/j.rce.2026.502520
Clinical outcomes of finerenone in heart failure: A systematic review and meta-analysis
Mylavarapu, M., Kiyani, M., Ndakotsu, A., Vats, V., Karnan, N., Palaparthi, E. C., Anjum, M., Kodali, L. S. M., Jamshed, A., & Cabrera, F. E. P. (2026) · World Journal of Cardiology · doi:10.4330/wjc.v18.i4.118879
Beyond Spironolactone: Does Next Generation of Aldosterone Blockade Add Value?
Li, S., Dreher, L., Danser, A. H. J., & Wenzel, U. O. (2026) · Hypertension · doi:10.1161/hypertensionaha.125.26376
Feola, M., Landra, F., Greco, C. A., Lorusso, R., & Ruocco, G. M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15083041 · Cited by 1
“Due to this evidence, finerenone was finally studied in HFpEF patients, demonstrating a significant reduction in composite outcomes, which were worsening heart failure (WHF) events and death from cardiovascular causes [46].”
Finerenone in Cardio-Oncology Patients With HFmrEF and HFpEF: Potential Clinical Benefits
Takahashi, T. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.04.024
Understanding Geographic Variations in Heart Failure Clinical Trials
Fazzini, L., Colombo, G., Tersalvi, G., Bruno, J., Inciardi, R. M., & d'Elia, E. (2026) · Current Heart Failure Reports · doi:10.1007/s11897-026-00753-0
Beyond phenogroups: towards a continuous biology of HFpEF
Störk, S., & Shimokawa, H. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag130
Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome
Zeitler, E. M., Klein, K. R., Lingvay, I., Pick, A., & Billings, L. K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70781 · Cited by 2
“However, further work is needed to test this hypothesis.”
Fioretti, F., Petrie, M. C., Dickert, N. W., & Butler, J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5086
Self-citationChowdhury, D., Mishra, A., Kumari, N., Manna, R., Sahoo, A., Kumar, P., & Bodakhe, S. H. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100704
Yao, H., Yang, X., Wang, Y., Wang, C., Sun, Y., Jiang, Y., Liang, L., Zhang, Q., Liu, H., Li, H., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70361
Kendrick, J., & Dixon, A. M. (2026) · Cardiorenal Medicine · doi:10.1159/000552030
Therapeutic Approach to Heart Failure Management: Insight from Clinical Trials
Kumar, A., Fowler, R., Ruggerio, E., Monahan, J., Battle, S. J., Ampadu, J. O., DiPette, D. J., & Potts, J. D. (2026) · Southern Medical Journal · doi:10.14423/smj.0000000000001965
D’Amario, D., Paglianiti, D. A., Laborante, R., Elia, S., Rizzo, G. E., Giubilato, S., Catalano, M. R., Amico, F., Volterrani, M., Restivo, A., et al. (2026) · European Heart Journal Open · doi:10.1093/ehjopen/oeag072
Jeong, G.-H. (2026) · Diabetology · doi:10.3390/diabetology7050084 · Cited by 1
Turner, A. J., Leboucher, C., Rémuzat, C., Fung, Y. M., Pessina, E., & Folkerts, K. (2026) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2026-0003
“The aim of this study was to assess the transportability of the FINEARTS-HF trial, a global RCT assessing the efficacy and safety of finerenone in addition to usual therapy in patients with HF and LVEF ≥ 40% [17] .”
InfluentialHou, Y., Zhao, J., Tang, Y., Liu, T., Zhang, Z., Wang, Z., & Shen, H. (2026) · iMetaMed · doi:10.1002/imm3.70042
Teh, J. W., Comerford, G., Surlis, G., Curneen, J. M. G., Krewer, F., Smyth, A., Lappin, D. W. P., McEvoy, J. W., Dennedy, M. C., & Judge, C. S. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004323 · Cited by 1
“In sensitivity analysis excluding trials with HFrEF, MRA remained significantly associated with all-cause mortality (OR, 0 91 [95% CI, 0.84–0.98]; ARR, 0.94% [95% CI, 0.15–1.73]) (Figure S6.”
InfluentialBaptista, R. (2026) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2026.04.003
“…horizon now belongs to finerenone: FINEARTS-HF demonstrated a 16% relative reduction in the composite of cardiovascular death and total HF events, 9 and its distinct pharmacological profile warrants dedicated testing in adequately phenotyped pre-clinical populations, with QoL prospectively…”
Left Ventricular Ejection Fraction in Heart Failure—A Parameter to Be Discontinued?
Freire, I., & da Silva, M. V. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103646
“More recently, the FINEARTS-HF trial demonstrated that the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone was also effective in the treatment of HFmrEF and HFpEF [26,83].”
Knezevic-Maragh, M., Gilani, F., Nandakumar, N. A., Hudli, A. R. M. Y., Puhachova, M., Zafar, W., Esther, P., AlGhaithi, A., Salman, N., & Bengherbia, L. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.05.009
Black, N., Soltani, F., Bradley, J., Williams, S. G., Reid, A. B., Nucifora, G., Schmitt, M., Petrie, M. C., & Miller, C. (2026) · Cureus · doi:10.7759/cureus.108732
“Such modelling needs to be revisited now that several effective treatments for HFpEF are available, including sodium-glucose cotransporter 2 inhibitors [25,26], glucagon-like 1 peptide receptor agonists [27,28], and mineralocorticoid receptor antagonists [29].”
Self-citation
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., Voors, A. A., Zannad, F., Abidin, I. Z., Alcocer-Gamba, M. A., Atherton, J. J., Bauersachs, J., Chang-Sheng, M., Chiang, C.-E., Chioncel, O., Chopra, V., Comin-Colet, J., Filippatos, G., Fonseca, C., Gajos, G., Goland, S., Goncalvesova, E., Kang, S., Katova, T., Kosiborod, M. N., Latkovskis, G., Lee, A. P.-W., Linssen, G. C. M., Llamas-Esperón, G., Mareev, V., Martinez, F. A., Melenovský, V., Merkely, B., Nodari, S., Petrie, M. C., Saldarriaga, C. I., Saraiva, J. F. K., Sato, N., Schou, M., Sharma, K., Troughton, R., Udell, J. A., Ukkonen, H., Vardeny, O., Verma, S., von Lewinski, D., Voronkov, L., Yilmaz, M. B., Zieroth, S., Lay-Flurrie, J., van Gameren, I., Amarante, F., Kolkhof, P., & Viswanathan, P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School, Boston (S.D.S., M.V., B.C., A.S.D.); British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (J.J.V.M., P.S.J., A.D.H., M.C.P.), and Bayer, Reading (J.L.-F.) — both in the United Kingdom; National Heart Centre Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); University of Michigan School of Medicine, Ann Arbor (B.P.); University of Milano-Bicocca and Papa Giovanni XXIII Hospital, Bergamo (M. Senni), and the Department of Cardiology, University of Brescia, and ASST “Spedali Civili” Hospital, Brescia (S.N.) — all in Italy; Northwestern University Feinberg School of Medicine, Chicago (S.J.S.); University Medical Center Groningen, Groningen (A.A.V.), the Department of Cardiology, Hospital Group Twente, Almelo (G.C.M.L.), and Bayer, Hoofddorp (I.G.) — all in the Netherlands; Université de Lorraine, INSERM Clinical Inv...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Vaduganathan, Muthiah
- Claggett, Brian
- Jhund, Pardeep S.
- Desai, Akshay S.
- Henderson, Alasdair D.
- Lam, Carolyn S.P.
- Pitt, Bertram
- Senni, Michele
- Shah, Sanjiv J.
- Voors, Adriaan A.
- Zannad, Faiez
- Abidin, Imran Zainal
- Alcocer-Gamba, Marco Antonio
- Atherton, John J.
- Bauersachs, Johann
- Chiang, Chern-En
- Chioncel, Ovidiu
- Chopra, Vijay
- Filippatos, Gerasimos
- Fonseca, Cândida
- Gajos, Grzegorz
- Goland, Sorel
- Kosiborod, Mikhail N.
- Latkovskis, Gustavs
- Lee, Alex Pui-Wai
- Linssen, Gerard C.M.
- Melenovský, Vojtěch
- Merkely, Béla
- Nodari, Savina
- Petrie, Mark C.
- Saldarriaga, Clara Inés
- Saraiva, Jose Francisco Kerr
- Sato, Naoki
- Schou, Morten
- Troughton, Richard
- Udell, Jacob A.
- Ukkonen, Heikki
- Vardeny, Orly
- Verma, Subodh
- von Lewinski, Dirk
- Voronkov, Leonid
- Zieroth, Shelley
- Kolkhof, Peter
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-24
- Volume
- 391
- Issue
- 16
- Pages
- 1475-1485
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4402101139
- Cited by
- 893
- References
- 21
- Citations by year
- 2026: 414 · 2025: 398 · 2024: 81
- FWCI
- 268.66
- Type
- journal article
- Language
- en
- Open access
- green
- hal.univ-lorraine.fr
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Bayer
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- finerenone, heart failure with mildly reduced ejection fraction, heart failure with preserved ejection fraction, mineralocorticoid receptor antagonists, non-steroidal mineralocorticoid receptor antagonists, cardiovascular mortality, hyperkalemia, hypokalemia, FINEARTS-HF trial, left ventricular ejection fraction, heart failure hospitalization, drug safety
- MeSH terms
- Aged, Aged, 80 and over, Mineralocorticoid Receptor Antagonists, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Naphthyridines, Stroke Volume, Treatment Outcome, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.